Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed.

1. Pharmacokinetic interaction between atorvastatin and fixed-dose combination of sofosbuvir/ledipasvir in healthy male Egyptian volunteers.European journal of clinical pharmacology · 2021
   Trial
2. Renal Manifestations of Chronic Hepatitis C: A Review.Journal of clinical medicine · 2024
   Review
3. The Impact of the G6PD Gene Mutations in Patients with Chronic Hepatitis C Infection Treated with Direct-Acting Antivirals: A Multicenter Observational Study.Genes · 2024
   Observational
4. Regiochemical Analysis of the ProTide Activation Mechanism.Biochemistry · 2024
   Article
5. A Quick and Sensitive LC-MS/MS Method for Simultaneous Quantification of Sofosbuvir Metabolite (GS-331007) in Human Plasma: Application to Hepatitis C Infected Patients with End-Stage Renal Disease.Middle East journal of digestive diseases · 2024
   Article
6. The Egyptian journey from having the highest prevalence of hepatitis C virus to being the first to achieve "gold tier" in conquering the disease.Proceedings (Baylor University. Medical Center) · 2024
   Article
7. Advancements in small molecule drug design: A structural perspective.Drug discovery today · 2023
   Review
8. Electrochemical sensor based on bio-inspired molecularly imprinted polymer for sofosbuvir detection.RSC advances · 2023
   Article
9. Promising Schiff bases in antiviral drug design and discovery.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2023
   Review
10. Quick and Sensitive UPLC-ESI-MS/MS Method for Simultaneous Estimation of Sofosbuvir and Its Metabolite in Human Plasma.Molecules (Basel, Switzerland) · 2019
    Article
11. Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation.PLoS pathogens · 2018
    Article
12. Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection.Infection and drug resistance · 2018
    Article
13. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.World journal of clinical cases · 2015
    Review
14. Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.PloS one · 2015
    Article
15. Phosphoramidates and phosphonamidates (ProTides) with antiviral activity.Antiviral chemistry & chemotherapy
    Review
16. Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies.Euroasian journal of hepato-gastroenterology
    Review
17. Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine.Journal of clinical and experimental hepatology
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract